Telo’s lead product is TeloView SMM, a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smouldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment.
These claims were validated by a study conducted in collaboration with the Mayo Clinic and Dr. Shaji Kumar in 2022-2023. In the study, a blinded cohort of 178 SMM patients were stratified to their respective risk groups by TeloView with greater than 80% accuracy. The achieved characteristics of the TeloView SMM assay outperform competitive tests that are currently available in the clinic.